ArticleAntimicrobial agents and chemotherapy2021
The AcrAB-TolC Efflux Pump Impacts Persistence and Resistance Development in Stationary-Phase Escherichia coli following Delafloxacin Treatment.
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Expression of multidrug efflux pump gene acrAB in Escherichia coli: a systematic review and meta analysis.BMC infectious diseases · 2025Pooled it
- Agricultural Pesticide Exposure and Antimicrobial Resistance inMicroorganisms · 2026Article
- Genome-wide network of antibiotic susceptibility in Pseudomonas aeruginosa.The Journal of antimicrobial chemotherapy · 2026Article
- Bioinformatics-Driven, Plant-Based Antibiotic Research Against Quorum Sensing and Biofilm Formation inBiomolecules · 2026Review
- Molecular Basis of Persister Awakening and Lag-Phase Recovery inInternational journal of molecular sciences · 2026Review
- Organosulfur compounds as dual-action agents: a critical review of antimicrobial and immunomodulatory potentials, and translational barriers.Frontiers in pharmacology · 2026Review
- Phenotype-First Diagnostic Framework for Tracking Fluoroquinolone Resistance inDiagnostics (Basel, Switzerland) · 2025Article
- Conservation and divergence of ciprofloxacin persister survival mechanisms between Pseudomonas aeruginosa and Escherichia coli.PLoS genetics · 2025Article
- Effect of host microenvironment and bacterial lifestyles on antimicrobial sensitivity and implications for susceptibility testing.npj antimicrobials and resistance · 2025Review
- Antibiotic-recalcitrant Salmonella during infection.Nature reviews. Microbiology · 2025Review
- Deciphering meropenem persistence inAntimicrobial agents and chemotherapy · 2025Article
- Advancements in Antibacterial Therapy: Feature Papers.Microorganisms · 2025Review
- Biochemistry of Bacterial Biofilm: Insights into Antibiotic Resistance Mechanisms and Therapeutic Intervention.Life (Basel, Switzerland) · 2025Review
- Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens.Frontiers in microbiology · 2025Review
- Intestinal biofilms: pathophysiological relevance, host defense, and therapeutic opportunities.Clinical microbiology reviews · 2024Review
- Agar and agarose used for Staphylococcus aureus biofilm cultivation impact fluoroquinolone tolerance.Journal of applied microbiology · 2024Article
- Article
- Intoxication of antibiotic persisters by host RNS inactivates their efflux machinery during infection.PLoS pathogens · 2024Article
- Bacterial Efflux Pump Inhibitors Reduce Antibiotic Resistance.Pharmaceutics · 2024Review
- Fluoroquinolone and beta-lactam antimicrobials induce different transcriptome profiles in Salmonella enterica persister cells.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Bacteria have a repertoire of strategies to overcome antibiotics in clinical use, complicating our ability to treat and cure infectious diseases. In addition to evolving resistance, bacteria within genetically clonal cultures can undergo transient phenotypic changes and tolerate high doses of antibiotics. These cells, termed persisters, exhibit heterogeneous phenotypes; the strategies that a bacterial population deploys to overcome one class of antibiotics can be distinct from those needed to survive treatment with drugs with another mode of action. It was previously reported that fluoroquinolones, which target DNA topoisomerases, retain the capacity to kill nongrowing bacteria that tolerate other classes of antibiotics. Here, we show that in Escherichia coli stationary-phase cultures and colony biofilms, persisters that survive treatment with the anionic fluoroquinolone delafloxacin depend on the AcrAB-TolC efflux pump. In contrast, we did not detect this dependence on AcrAB-TolC in E. coli persisters that survive treatment with three other fluoroquinolone compounds. We found that the loss of AcrAB-TolC activity via genetic mutations or chemical inhibition not only reduces delafloxacin persistence in nongrowing E. coli MG1655 or EDL933 (an E. coli O157:H7 strain), but it limits resistance development in progenies derived from delafloxacin persisters that were given the opportunity to recover in nutritive medium following antibiotic treatment. Our findings highlight the heterogeneity in defense mechanisms that persisters use to overcome different compounds within the same class of antibiotics. They further indicate that efflux pump inhibitors can potentiate the activity of delafloxacin against stationary-phase E. coli and block resistance development in delafloxacin persister progenies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.